Edwards Lifesciences Corp (EW)

Sep 26, 2026

Edwards Lifesciences (NYSE:EW) has received a "Moderate Buy" rating from analysts, with an average target price of $100.27, suggesting an upside from its current share price of $86.39. The company recently surpassed quarterly earnings and revenue expectations and has significant institutional ownership. Despite some insider selling, analysts maintain a positive outlook, with several firms reiterating "buy" or "outperform" ratings and increasing price targets.

Sep 23, 2026

Andra AP fonden has significantly increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 49.0% in the second quarter, now owning 171,269 shares valued at $15.49 million. Other institutional investors have also adjusted their holdings in the medical research company. Edwards Lifesciences reported strong Q2 earnings, beating analyst estimates, and has received a "Moderate Buy" consensus rating from analysts with an average target price of $100.27.

Sep 16, 2026

Bank of America Corp DE has acquired a significant new stake in Edwards Lifesciences Corporation (NYSE:EW), purchasing over 6.69 million shares valued at approximately $605.40 million during the second quarter. This move makes Bank of America Corp DE a 1.16% owner of Edwards Lifesciences. Other institutional investors have also adjusted their holdings, while several analysts have issued "buy" or "outperform" ratings for the stock with price targets around $100-$110.

Sep 16, 2026

Edwards Lifesciences and Medtronic, leading medtech companies, have received positive news from CMS regarding expanded Medicare coverage for Transcatheter Aortic Valve Replacement (TAVR). CMS's finalized national coverage decision will now include patients with asymptomatic severe aortic stenosis and removes the evidence development requirement for symptomatic cases. This move is expected to streamline patient care, increase TAVR procedure volumes, and reinforces the value of multidisciplinary heart teams.

Sep 14, 2026

Edwards Lifesciences (NYSE: EW) experienced a significant surge in options trading activity, with traders purchasing 2,518 call options, a 93% increase over the average daily volume. The company recently exceeded quarterly earnings expectations, reporting $0.78 EPS and $1.74 billion in revenue, leading to a "Moderate Buy" consensus rating from analysts with an average price target of $100.27. Despite some insider selling, institutional investors have substantially increased their holdings in the medical technology firm.

Sep 14, 2026

Edwards Lifesciences executive Daniel Lippis exercised options for 619 shares at $72.68 each and subsequently sold them for $87.51 per share on September 11, 2026. Following this transaction, Lippis retained 40,034 shares and 3,714 derivative securities. The exercised options represented approximately 14.3% of his previous derivative securities holdings, while the shares sold were about 1.5% of his total shareholding before the sale.

Sep 14, 2026

Corient Private Wealth LP significantly increased its stake in Edwards Lifesciences Corporation by over 1,000%, acquiring an additional 227,947 shares. This move is part of a broader trend of institutional investors, including California State Teachers Retirement System and BlackRock Inc., increasing their holdings in the medical research company. The article also details recent analyst ratings, insider trading activity, and positive news regarding CMS expanding TAVR coverage, which is expected to boost demand for Edwards Lifesciences' products.